Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$176.37-0.6%$171.25$140.68▼$181.16$425.17B0.48.85 million shs3.06 million shsNVAXNovavax$8.58+6.1%$7.69$5.01▼$15.22$1.39B2.686.67 million shs4.37 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-0.34%-0.45%+0.41%+16.48%+7.23%NVAXNovavax+1.25%+4.53%-15.66%+24.50%-40.63%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$176.37-0.6%$171.25$140.68▼$181.16$425.17B0.48.85 million shs3.06 million shsNVAXNovavax$8.58+6.1%$7.69$5.01▼$15.22$1.39B2.686.67 million shs4.37 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson-0.34%-0.45%+0.41%+16.48%+7.23%NVAXNovavax+1.25%+4.53%-15.66%+24.50%-40.63%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.65Moderate Buy$176.29-0.05% DownsideNVAXNovavax 2.13Hold$14.2966.60% UpsideCurrent Analyst Ratings BreakdownLatest JNJ and NVAX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/28/2025NVAXNovavaxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.008/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$185.00 ➝ $200.008/20/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform$9.00 ➝ $7.007/23/2025JNJJohnson & JohnsonErste Group BankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy7/22/2025NVAXNovavaxBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.007/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$180.00 ➝ $190.007/17/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$164.00 ➝ $167.007/17/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$161.00 ➝ $175.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$88.82B4.78$13.00 per share13.57$29.69 per share5.94NVAXNovavax$682.16M2.04N/AN/A($3.89) per share-2.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$9.3518.8815.932.2725.00%32.49%13.00%10/14/2025 (Estimated)NVAXNovavax-$187.50M$2.283.75107.190.1139.20%-142.33%28.65%11/11/2025 (Estimated)Latest JNJ and NVAX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/14/2025Q3 2025JNJJohnson & Johnson$2.78N/AN/AN/A$23.73 billionN/A8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 million7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.202.95%N/A55.61%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest JNJ and NVAX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.501.010.76NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableJNJ and NVAX HeadlinesRecent News About These CompaniesWhy Avoid Pfizer, BioNTech, Novavax, and ModernaSeptember 15 at 11:13 AM | baystreet.caCOVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child DeathsSeptember 15 at 10:01 AM | zacks.comBayforest Capital Ltd Purchases New Stake in Novavax, Inc. $NVAXSeptember 13 at 4:45 AM | marketbeat.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowSeptember 10, 2025 | zacks.comPark West Asset Management LLC Acquires New Position in Novavax, Inc. $NVAXSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Reduces Position in Novavax, Inc. $NVAXSeptember 8, 2025 | marketbeat.comNovavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeptember 4, 2025 | seekingalpha.comNuvaxovid® Now Approved in Japan Triggering Takeda Milestone PaymentSeptember 4, 2025 | prnewswire.comNovavax ‘applauds’ President Trump’s call for available COVID-19 vaccine dataSeptember 4, 2025 | msn.comNovavax to Participate in the Cantor Global Healthcare ConferenceSeptember 3, 2025 | finance.yahoo.comOMERS ADMINISTRATION Corp Takes $1.28 Million Position in Novavax, Inc. $NVAXSeptember 3, 2025 | marketbeat.comOptimistic Outlook on Novavax: Strategic Positioning and Vaccine Developments Drive Buy RatingSeptember 2, 2025 | tipranks.comRafferty Asset Management LLC Sells 80,502 Shares of Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comInvesco Ltd. Boosts Stake in Novavax, Inc. $NVAXSeptember 2, 2025 | marketbeat.comFY2025 Earnings Forecast for Novavax Issued By HC WainwrightSeptember 2, 2025 | marketbeat.comNuveen LLC Purchases New Position in Novavax, Inc. $NVAXSeptember 1, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 1, 2025 | marketbeat.comQ3 Earnings Forecast for Novavax Issued By HC WainwrightAugust 31, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Novavax (NASDAQ:NVAX)August 30, 2025 | marketbeat.comKohl’s, Bill.com, Novavax, Jazz, Nvidia: Trending by AnalystsAugust 30, 2025 | tipranks.comNovavax, Inc. (NVAX) Wins FDA Approval for Nuvaxovid BLAAugust 29, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025JNJ and NVAX Company DescriptionsJohnson & Johnson NYSE:JNJ$176.37 -1.03 (-0.58%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$8.57 +0.50 (+6.13%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
